Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
By E. Van Cutsem, H. van de Velde, P. Karásek, H. Oettle, W. Vervenne, A. Szawłowski, P. Schőffski, S. Post, C. Verslype, H. Neumann and 5 more. Journal of Clinical Oncology, 2004
788 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/06567cd1efaab0ce57ace8f29730452119a82fb3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Surgery
Citations in the corpus
- Genetics and biology of pancreatic ductal adenocarcinoma. (2006, background): “Despite showing promise in vitro and in PDAC xenografts (Omer and Kohl 1997), farnysltransferase inhibitors (FTIs), which inhibit a lipid modification of the C terminus of RAS proteins, have not been clinically effective (Van Cutsem et al. 2004).”
- Pancreatic cancers require autophagy for tumor growth. (2011, neutral): “Unfortunately, effective KRAS inhibitors have yet to be developed (Van Cutsem et al. 2004).”
- Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. (2009, background): “Several new targeted agents have been studied in phase III trials in combination with gemcitabine, including marimastat, tipifarnib, cetuximab, and erlotinib.(23,24) Only the combination of gemcitabine and erlotinib proved to be more active than gemcitabine alone.”
- Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010, background): “Negative phase III results despite promising single-arm phase II data are, unfortunately, a common outcome in pancreatic cancer trials.(3-10) These collective data suggest that in this disease, a single-arm, phase II trial design may not be not optimal.”